NCLT clears Orchid-Dhanuka merger. Integration starts now.
The Chennai bench approved the scheme on Friday, turning a March announcement into an executable deal. The order copy is awaited.
— 5 earlier stories on Orchid Pharma Ltd. →What's new
- NCLT Chennai approved the merger of Dhanuka Laboratories into Orchid Pharma.
- The scheme, first announced in March, transfers all assets and liabilities on a going-concern basis.
- The court's order copy is awaited, which will detail the final terms.
Why this matters
Court approval turns an announced plan into an executable deal. For Orchid, a small-cap pharma firm, folding Dhanuka Labs in removes the last regulatory hurdle to consolidating under the Dhanuka Group umbrella. The exact financial impact isn't yet public, but the path is clear.
What we're watching
- The awaited NCLT order copy, which will detail any conditions attached to the sanction.
- The timeline for integration and any asset/liability specifics.
- How the combined entity's scale affects its competitive position.
The full read
The NCLT Chennai bench approved the merger of Dhanuka Laboratories into Orchid Pharma on Friday. This is the final regulatory hurdle cleared. The scheme, first announced in March, transfers all assets and liabilities on a going-concern basis. It allows the small-cap pharma firm to consolidate under the Dhanuka Group. The order copy is awaited and will set the precise terms. The deal's strategic logic is operational consolidation. But the financial scale of the integration remains undisclosed. The approval shifts the story from announcement to implementation. Not yet complete, though. Integration is the real test.
Questions answered
- What did the NCLT approve on Friday?
- The tribunal approved the scheme of amalgamation to merge Dhanuka Laboratories entirely into Orchid Pharma. All assets and liabilities will transfer on a going-concern basis.
- How long has this merger been in the works?
- The scheme was first announced in March. It has taken from then until now to receive the final regulatory sanction from the NCLT.
- What is the immediate next step?
- The company is awaiting the detailed copy of the NCLT order. This document will formalize the terms and any conditions attached to the approval.
- What is the strategic rationale for the merger?
- The rationale states the deal allows for consolidation under the Dhanuka Group, which could streamline operations and potentially create cost synergies. The exact financial impact remains unquantified.
Story so far
All notes on ORCHPHARMA →- 5 Jun 2026 · 5:30 PM IST NCLT clears Orchid-Dhanuka merger. Integration starts now.
- 4d ago Orchid expects Enmetazobactam deal this quarter, eyes US sterile market
- 10d ago Orchid Pharma lifts Enmetazobactam lifetime sales target to $2 billion
- 11d ago Orchid Pharma annual profit drops to ₹45.2 crore
- 11d ago Orchid Pharma profit falls 57% on higher costs; auditor flags US units